3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
2
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Bevacizumab
6
Nivolumab
5
pembrolizumab
4
Gemcitabine
4
Cisplatin
3
regorafenib
2
fludarabine
2
Sorafenib
2
Paclitaxel
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Drug Therapy
2
Cyclophosphamide
2
Azacitidine
2
vocimagene amiretrorepvec
1
ulixertinib
1
temsirolimus
1
spartalizumab
1
sonidegib
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
pazopanib
1
olutasidenib
1
olaparib
1
motexafin gadolinium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
bemcentinib
×
Gastrointestinal
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts